Tango Therapeutics Stock Analysis

TNGX Stock  USD 3.10  0.16  5.44%   
Tango Therapeutics is undervalued with Real Value of 6.69 and Target Price of 17.6. The main objective of Tango Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Tango Therapeutics is worth, separate from its market price. There are two main types of Tango Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Tango Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tango Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Tango Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Tango Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.45. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tango Therapeutics recorded a loss per share of 1.15. The entity had not issued any dividends in recent years. Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people. To find out more about Tango Therapeutics contact Barbara MD at 857 320 4900 or learn more at https://www.tangotx.com.

Tango Therapeutics Investment Alerts

Tango Therapeutics generated a negative expected return over the last 90 days
Tango Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 36.53 M. Net Loss for the year was (101.74 M) with loss before overhead, payroll, taxes, and interest of (81.05 M).
Tango Therapeutics currently holds about 416.36 M in cash with (117.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Tango Therapeutics has a poor financial position based on the latest SEC disclosures
Over 87.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Tango Therapeutics, Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBeat

Tango Therapeutics Upcoming and Recent Events

Earnings reports are used by Tango Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
25th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Tango Largest EPS Surprises

Earnings surprises can significantly impact Tango Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-06
2021-06-30-0.145-0.16-0.01510 
2024-05-08
2024-03-31-0.31-0.35-0.0412 
2024-03-18
2023-12-31-0.28-0.32-0.0414 
View All Earnings Estimates

Tango Therapeutics Environmental, Social, and Governance (ESG) Scores

Tango Therapeutics' ESG score is a quantitative measure that evaluates Tango Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Tango Therapeutics' operations that may have significant financial implications and affect Tango Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Tango Stock Institutional Investors

Shares
Balyasny Asset Management Llc2024-09-30
2.7 M
State Street Corp2024-09-30
2.3 M
Adage Capital Partners Gp Llc2024-09-30
2.3 M
Deerfield Management Co2024-09-30
1.5 M
Geode Capital Management, Llc2024-09-30
1.4 M
Casdin Capital, Llc2024-09-30
1.2 M
Baker Bros Advisors Lp2024-09-30
750 K
Arrowmark Colorado Holdings, Llc (arrowmark Partners)2024-09-30
708.4 K
Bessemer Group Inc2024-09-30
708.4 K
Trv Gp Iv, Llc2024-09-30
16.9 M
Ecor1 Capital, Llc2024-09-30
13.3 M
Note, although Tango Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tango Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 333 M.

Tango Profitablity

The company has Profit Margin (PM) of (2.84) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.83) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.83.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.25)(0.27)
Return On Capital Employed(0.32)(0.34)
Return On Assets(0.25)(0.27)
Return On Equity(0.40)(0.42)

Management Efficiency

Tango Therapeutics has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4879) %, meaning that it created substantial loss on money invested by shareholders. Tango Therapeutics' management efficiency ratios could be used to measure how well Tango Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.34 in 2024. At this time, Tango Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.15 in 2024, whereas Total Assets are likely to drop slightly above 352.5 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 2.68  2.10 
Tangible Book Value Per Share 2.68  2.14 
Enterprise Value Over EBITDA(8.13)(8.54)
Price Book Value Ratio 3.70  6.45 
Enterprise Value Multiple(8.13)(8.54)
Price Fair Value 3.70  6.45 
Enterprise Value908.8 M954.2 M
At Tango Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Operating Margin
(2.83)
Profit Margin
(2.84)
Beta
0.879
Return On Assets
(0.22)
Return On Equity
(0.49)

Technical Drivers

As of the 22nd of December, Tango Therapeutics has the Variance of 45.91, risk adjusted performance of (0.14), and Coefficient Of Variation of (546.17). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tango Therapeutics, as well as the relationship between them.

Tango Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tango Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tango Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Tango Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tango Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tango Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tango Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Rothenberg Mace over a month ago
Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.78 subject to Rule 16b-3
 
Rothenberg Mace over a month ago
Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.62 subject to Rule 16b-3
 
Ecor1 Capital, Llc over a month ago
Disposition of 1143124 shares by Ecor1 Capital, Llc of Tango Therapeutics at 2.9171 subject to Rule 16b-3
 
Davis Aaron I. over a month ago
Acquisition by Davis Aaron I. of 65000 shares of Tango Therapeutics at 10.93 subject to Rule 16b-3
 
Peters Malte over a month ago
Acquisition by Peters Malte of 6250 shares of Tango Therapeutics subject to Rule 16b-3
 
Boxer Capital Management, Llc over a month ago
Disposition of 633000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.87 subject to Rule 16b-3
 
Boxer Capital Management, Llc over two months ago
Disposition of 250000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.78 subject to Rule 16b-3
 
Boxer Capital Management, Llc over two months ago
Disposition of 625000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 7.05 subject to Rule 16b-3
 
Boxer Capital Management, Llc over two months ago
Insider Trading
 
Third Rock Ventures Iv, L.p. over three months ago
Disposition of 75000 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 11.5618 subject to Rule 16b-3
 
Davis Aaron I. over three months ago
Acquisition by Davis Aaron I. of 65000 shares of Tango Therapeutics at 10.93 subject to Rule 16b-3
 
Third Rock Ventures Iv, L.p. over three months ago
Disposition of 25000 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 11.5466 subject to Rule 16b-3

Tango Therapeutics Outstanding Bonds

Tango Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tango Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tango bonds can be classified according to their maturity, which is the date when Tango Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Tango Therapeutics Predictive Daily Indicators

Tango Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tango Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tango Therapeutics Corporate Filings

6th of December 2024
Other Reports
ViewVerify
13A
20th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
F4
18th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
8th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
7th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
6th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
28th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
23rd of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Tango Therapeutics Forecast Models

Tango Therapeutics' time-series forecasting models are one of many Tango Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tango Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Tango Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tango Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tango shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tango Therapeutics. By using and applying Tango Stock analysis, traders can create a robust methodology for identifying Tango entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(2.78)(2.92)
Operating Profit Margin(3.13)(3.28)
Net Loss(2.79)(2.92)
Gross Profit Margin(2.15)(2.05)

Current Tango Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tango analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tango analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.6Strong Buy9Odds
Tango Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Tango analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tango stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tango Therapeutics, talking to its executives and customers, or listening to Tango conference calls.
Tango Analyst Advice Details

Tango Stock Analysis Indicators

Tango Therapeutics stock analysis indicators help investors evaluate how Tango Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tango Therapeutics shares will generate the highest return on investment. By understating and applying Tango Therapeutics stock analysis, traders can identify Tango Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow64 M
Common Stock Shares Outstanding94.6 M
Total Stockholder Equity253.1 M
Tax Provision138 K
Property Plant And Equipment Net53.4 M
Cash And Short Term Investments336.9 M
Cash66.4 M
Accounts Payable2.8 M
Net Debt-27.5 M
50 Day M A4.5298
Total Current Liabilities45.9 M
Other Operating Expenses150.7 M
Non Current Assets Total56 M
Non Currrent Assets Other2.6 M
Stock Based Compensation19.1 M

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.